| Literature DB >> 26274957 |
Jianzhong Li1, Jing Xu2,3, Weiheng Xu4, Yang Qi5, Yiming Lu6, Lei Qiu7, Zhenlin Hu8, Zhiyong Chu9, Yifeng Chai10, Junping Zhang11.
Abstract
Hong Shan Capsule (HSC), a crude drug of 11 medicinal herbs, was used in clinical practice for the treatment of radiation injuries in China. In this study, we investigated its protection in rats against acute lethal total-body irradiation (TBI). Pre-administration of HSC reduced the radiation sickness characteristics, while increasing the 30-day survival of the irradiated rats. Administration of HSC also reduced the radiation sickness characteristics and increased the 30-day survival of mice after exposure to lethal TBI. Ultrastructural observation illustrated that the pretreatment of rats with HSC significantly attenuated the TBI-induced morphological changes in the different organs of irradiated rats. Gene expression profiles revealed the dramatic effect of HSC on alterations of gene expression caused by lethal TBI. Pretreatment with HSC prevented differential expression of 66% (1398 genes) of 2126 genes differentially expressed in response to TBI. Pathway enrichment analysis indicated that these genes were mainly involved in a total of 32 pathways, such as pathways in cancer and the mitogen-activated protein kinase (MAPK) signaling pathway. Our analysis indicated that the pretreatment of rats with HSC modulated these pathways induced by lethal TBI, such as multiple MAPK pathways, suggesting that pretreatment with HSC might provide protective effects on lethal TBI mainly or partially through the modulation of these pathways. Our data suggest that HSC has the potential to be used as an effective therapeutic or radio-protective agent to minimize irradiation damage.Entities:
Keywords: Hong Shan capsule (HSC); gene expression; lethal total-body irradiation; radioprotection; signaling pathways
Mesh:
Substances:
Year: 2015 PMID: 26274957 PMCID: PMC4581280 DOI: 10.3390/ijms160818938
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Comparison of survival curves by using the Kaplan–Meier method. (A) 30-day survival of rats (n = 10 per group) pretreated with HSC (2.5, 5, and 10 g/kg) before exposure to 7 Gy TBI. The survival curves were significantly different as predicted by the log rank test. (p = 0.0499); (B) 30-day survival of rats (n = 10 per group) pretreated with HSC (10 g/kg) before exposure to 6 Gy TBI. The survival curves were significantly different as predicted by the log rank test. (p = 0.0120); (C) 30-day survival of mice (n = 12 per group) pretreated with HSC (2.5, 5 and 10 g/kg) before exposure to 8.5 Gy TBI. The survival curves were significantly different as predicted by the log rank test. (p < 0.0001); and (D) 30-day survival of mice (n = 11 per group) treated with HSC (2.5, 5 and 10 g/kg) after exposure to 8 Gy TBI. The survival curves were significantly different as predicted by the log rank test. (p = 0.0014).
Figure 2Effect of HSC on radiation-induced tissues injury at one day after exposure to lethal TBI (6.5 Gy) using transmission electron microscopy. (A1–7) Representative photographs of non-irradiated rats; (B1–7) Representative photographs of 10 TBI rats. Cell swelling and large amounts of cytoplasmic vacuoles (arrows) were observed in the different tissues at one day after exposure to lethal TBI (6.5 Gy); (C1–7) Representative photographs of 10 irradiated rats pretreated with HSC (10 g/kg) once each day for three consecutive days before exposure to 6.5 Gy TBI. HSC pretreatment attenuated the radiation-induced tissue injury such as cytoplasmic vacuoles (arrows). (Uranyl acetate and lead citrate staining, 3000×).
Figure 3Cluster analysis of individual rats according to the profile of gene expression examined. Genes are organized by hierarchical clustering based on overall similarity in expression patterns. Red represents relative expression greater than the median expression level across all samples, and green represents an expression level lower than the median. Black indicates intermediate expression. Rats from the same treatment group (6.5 Gy TBI, 10 g/kg HSC + 6.5 Gy TBI) were the closest.
Figure 4GO ontology analysis of genes for which radiation-induced alteration of expression was abolished or attenuated by HSC. Gene ontology (level 2) for the transcriptome under Molecular_function, Cellular_component, and Biological_process.
KEGG pathway analysis of genes for which radiation-induced alteration of expression was abolished or attenuated by HSC.
| Name | Hits | Percent | Enrichment Test |
|---|---|---|---|
| Olfactory transduction | 41 | 3.96% | 0.0064 |
| Neuroactive ligand-receptor interaction | 16 | 5.63% | 0.0043 |
| Pathways in cancer | 15 | 4.66% | 0.0251 |
| Calcium signaling pathway | 13 | 6.99% | 0.0017 |
| Vascular smooth muscle contraction | 11 | 9.09% | 5.00 × 10−4 |
| Gap junction | 10 | 11.24% | 2.00 × 10−4 |
| Cytokine-cytokine receptor interaction | 10 | 4.83% | 0.0494 |
| MAPK signaling pathway | 10 | 3.72% | 0.1465 |
| Systemic lupus erythematosus | 9 | 6.77% | 0.0101 |
| Purine metabolism | 9 | 5.39% | 0.035 |
| PPAR signaling pathway | 9 | 11.39% | 4.00 × 10−4 |
| Tight junction | 8 | 6.02% | 0.0269 |
| GnRH signaling pathway | 8 | 8.08% | 0.0058 |
| Axon guidance | 8 | 6.30% | 0.0214 |
| ECM-receptor interaction | 7 | 9.21% | 0.005 |
| Protein digestion and absorption | 6 | 7.69% | 0.0195 |
| Wnt signaling pathway | 6 | 3.90% | 0.2176 |
| Hematopoietic cell lineage | 6 | 7.59% | 0.0205 |
| Adipocytokine signaling pathway | 6 | 8.57% | 0.0124 |
| Jak-STAT signaling pathway | 6 | 4.08% | 0.1902 |
| Acute myeloid leukemia | 6 | 10.71% | 0.0047 |
| Notch signaling pathway | 5 | 10.00% | 0.0124 |
| Glutathione metabolism | 5 | 8.93% | 0.0187 |
| Fatty acid metabolism | 5 | 10.42% | 0.0106 |
| Bile secretion | 5 | 6.76% | 0.0494 |
| Starch and sucrose metabolism | 4 | 8.51% | 0.0394 |
| Staphylococcus aureus infection | 4 | 8.16% | 0.0444 |
| Mineral absorption | 4 | 8.70% | 0.037 |
| Galactose metabolism | 4 | 16.00% | 0.0058 |
| Circadian rhythm | 4 | 19.05% | 0.0033 |
| Carbohydrate digestion and absorption | 4 | 10.53% | 0.021 |
| ABC transporters | 4 | 8.89% | 0.0347 |
The 10 genes that were involved in the MAPK pathways.
| Gene ID | Symbol | Description | Fold Change | |
|---|---|---|---|---|
| TBI | HSC + TBI | |||
| 24577 | Myc | Myelocytomatosis oncogene | 3.41 | 2.03 |
| 29692 | Pla2g2a/sPLA2 | Phospholipase A2, group IIA | 5.65 | 4.25 |
| 501563 | Prkx | Protein kinase, X-linked | 1.58 | 1.32 |
| 54234 | Cacna1e | Calcium channel, voltage-dependent, R type, α 1E subunit | 2.14 | 1.10 |
| 682930 | Cacna1s | Calcium channel, voltage-dependent, L type, α 1S subunit | 3.30 | 1.04 |
| 301343 | Map4k4 | Mitogen-activated protein kinase kinase kinase kinase 4 | 1.75 | 1.37 |
| 64666 | Taok2 | TAO kinase 2 | 1.66 | 0.93 |
| 79255 | Atf4 | Activating transcription factor 4 | 1.54 | 1.11 |
| 365057 | Ask1 | Similar to apoptosis signal-regulating kinase 1 | 0.42 | 0.85 |
| 59109 | Ntrk1 | Neurotrophic tyrosine kinase, receptor, type 1 | 0.29 | 0.58 |
The nine genes that were involved in the PPAR signaling pathway.
| Gene ID | Symbol | Description | Fold Change | |
|---|---|---|---|---|
| TBI | HSC + TBI | |||
| 25682 | Ppard | Peroxisome proliferator-activated receptor delta | 1.88 | 0.89 |
| 94340 | Acsl5 | Acyl-CoA synthetase long-chain family member 5 | 1.67 | 1.34 |
| 266674 | Cyp4a8 | Cytochrome P450, family 4, subfamily a, polypeptide 8 | 3.35 | 2.56 |
| 501072 | Acaa1b | Acetyl-Coenzyme A acyltransferase 1B | 1.85 | 1.35 |
| 50549 | Cyp4a1 | Cytochrome P450, family 4, subfamily a, polypeptide 1 | 1.93 | 1.36 |
| 25756 | Cpt1b | Carnitine palmitoyltransferase 1b, muscle | 2.11 | 1.39 |
| 79223 | Gk | Glycerol kinase | 1.52 | 1.32 |
| 25747 | Ppara | Peroxisome proliferator activated receptor alpha | 0.66 | 0.99 |
| 24552 | Me1 | Malic enzyme 1, NADP(+)-dependent, cytosolic | 0.67 | 0.74 |
The eight genes that were involved in the GnRH signaling pathway.
| Gene ID | Symbol | Description | Fold Change | |
|---|---|---|---|---|
| TBI | HSC + TBI | |||
| 25433 | Hbegf | Heparin-binding EGF-like growth factor | 2.50 | 1.46 |
| 81686 | Mmp2 | Matrix metallopeptidase 2 | 1.74 | 1.50 |
| 682930 | Cacna1s | Calcium channel, voltage-dependent, L type, α 1S subunit | 3.30 | 1.04 |
| 29692 | Pla2g2a | Phospholipase A2, group IIA | 5.65 | 4.25 |
| 83805 | Src | V-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog | 1.62 | 1.16 |
| 79255 | Atf4 | Activating transcription factor 4 | 1.54 | 1.11 |
| 501563 | Prkx | Protein kinase, X-linked | 1.58 | 1.32 |
| 25679 | Itpr3 | Inositol 1,4,5-trisphosphate receptor, type 3 | 0.58 | 0.84 |
The six genes that were involved in the Wnt signaling pathway.
| Gene ID | Symbol | Description | Fold Change | |
|---|---|---|---|---|
| TBI | HSC + TBI | |||
| 114850 | Wnt7a | Wingless-type MMTV integration site family, member 7A | 1.63 | 0.99 |
| 64512 | Fzd2 | Frizzled family receptor 2 | 2.95 | 2.16 |
| 293649 | Lrp5 | Low density lipoprotein receptor-related protein 5 | 1.57 | 1.12 |
| 25682 | Ppard | Peroxisome proliferator-activated receptor Δ | 1.88 | 0.89 |
| 501563 | Prkx/PKA | Protein kinase, X-linked | 1.58 | 1.32 |
| 24577 | Myc | Myelocytomatosis oncogene | 3.41 | 2.03 |
The five genes that were involved in the Notch signaling pathway.
| Gene ID | Symbol | Description | Fold Change | |
|---|---|---|---|---|
| TBI | HSC + TBI | |||
| 79225 | Hes5 | hes family bHLH transcription factor 5 | 2.28 | 1.70 |
| 360801 | Ncor2 | nuclear receptor co-repressor 2 | 1.61 | 1.31 |
| 116462 | Ptcra | pre T-cell antigen receptor α | 1.81 | 1.08 |
| 362268 | Rbpjl | recombination signal binding protein for immunoglobulin kappa J region-like | 2.29 | 1.08 |
| 300802 | Aph1b | APH1B gamma secretase subunit | 0.56 | 0.70 |
To validate the consistency of microarray analysis in the present study, we compared gene expression levels of eight selected genes (Myc (MAPK pathways and Wnt signaling pathway), Ntrk1 (MAPK pathways), Atf4 (MAPK pathways and GnRH signaling pathway), Cacna1s (GnRH signaling pathway), Ctf1 (cardiotrophin 1, Cytokine-cytokine receptor interaction and Jak-STAT signaling pathway), Ppard (Wnt signaling pathway and PPAR signaling pathway), Wnt7a and Prkx (Wnt signaling pathway)) between microarray and real-time PCR. We determined the mean value of expression of the selected genes in five independent rats from each treatment group. This was compared with those in pooled RNA from five non-irradiated rats. The qualitative changes in gene expression levels were consistent between microarray and real-time PCR (Figure 5).
Figure 5Quantitative real-time PCR confirmation of the microarray data. qRT-PCR was performed on eight genes where TBI-induced alteration of expression was abolished or attenuated by 10 mg/kg HSC pretreatment. RNA samples of different groups (n = 5 per group) were prepared 24 h after exposure to 6.5 Gy TBI. Gene expression levels are shown as the mean normalized to the expression of the housekeeping gene beta-actin. Each sample was measured in triplicate. Columns, the mean of three or four rats in the microarray experiment or the mean of five rats in PCR; bars, SD. * indicates statistical significance compared to control (non-irradiation) by t-test, * p < 0.05. Comparison of fold change produced by microarray with relative expression ratio obtained from real-time PCR with good concordance.
Oligonucleotides primers used in this study for quantitative real-time-PCR analysis. The primer sequences were designed by using the ProbeFinder version 2.49 (http://www.roche-applied-science.com).
| Gene ID | Symbol | Primer | Sequence |
|---|---|---|---|
| 79255 | Atf4 | Forward | tcagacaccggcaaggag |
| Reverse | gtggccaaaagctcatctg | ||
| 682930 | Cacna1s | Forward | gcgtcgtggagtggaaac |
| Reverse | ctctggcatgggcaggta | ||
| 24577 | Myc | Forward | gaatttttgtctatttggggaca |
| Reverse | gcatcgtcgtgactgtcg | ||
| 114850 | Wnt7a | Forward | ccctcatgaacttacacaataacg |
| Reverse | tggcacttacactccagtttcat | ||
| 501563 | Prkx | Forward | gcctgggcaacatgaaga |
| Reverse | tccacacctcggaaccac | ||
| 29201 | Ctf1 | Forward | tcctgaccaaatatgcagacc |
| Reverse | agggctctccctgttgct | ||
| 25682 | Ppard | Forward | ggaccagagcacacccttc |
| Reverse | gaggaaggggaggaattctg | ||
| 59109 | Ntrk1 | Forward | cagcttctggctgtggcta |
| Reverse | aagtgcaggctggctaggta | ||
| 81822 | β-Actin | Forward | cccgcgagtacaaccttct |
| Reverse | cgtcatccatggcgaact |